Compare Amylx Pharmaceuticals Inc (AMLX) vs Rivian Automotive, Inc. (RIVN) Price & Performance

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Rivian (RIVN) trades at $16.39, up 2.44% today, showing bullish technical signals with recent price momentum. The company continues to narrow losses, with Q2 2026 EPS beating expectations at -$0.47 versus -$0.66 expected. Revenue growth is steady, reaching $5.39B in 2025, while cash burn remains a key focus as the R2 vehicle ramp-up progresses.

Outlook is cautiously optimistic with analyst consensus price target of $18.70 offering potential upside. Key opportunities include R2 demand and margin improvements, but risks from high cash burn and competitive pressures persist. Execution on profitability targets will be critical for sustained stock appreciation.